Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines(Extension Study)

Daewoong Pharmaceutical

Status and phase: Unknown; Phase 3

Conditions: Glabellar Lines; Crow's Feet Lines

Treatments: Drug: Clostridium Botulinum A Toxin

Study type: Interventional

Funder types: Industry

Identifiers

NCT03184363

DW_DWP450005E

Details and patient eligibility

About

The purpose of this study is to explore the Efficacy and Safety of DWP450 for treating Crows Feet Lines(CFL) in combination with glabellar line(GL) as extension study of phase 3 study for CFL.

Enrollment: 102 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Male or female of at least 18 to 75 years old
• moderate-to-severe CFL at maximum smile on the FWS as rated by the investigator
• moderate-to-severe GL at maximum frawn on the FWS as rated by the investigator
• Subject who has completed phase 3 study for CFL.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

102 participants in 1 patient group

Clostridium Botulinum A Toxin

Experimental group

Description:

Clostridium Botulinum A Toxin

Treatment:

Drug: Clostridium Botulinum A Toxin